About This Calculator

The Basal–Bolus Insulin Calculator is a clinical tool designed to help healthcare professionals establish an initial insulin dosing schedule for adult patients with Type 1 or Type 2 diabetes. It provides a starting point for therapy based on patient weight, clinical status, and glycemic goals, which must be titrated based on individual response and glucose monitoring.

Outputs Explained

The calculator provides a comprehensive initial insulin regimen, broken down into the following key components:

• Total Daily Dose (TDD): The total number of insulin units estimated for a 24-hour period.
• Basal Insulin Dose: The portion of the TDD provided by long-acting insulin to cover background glucose needs. The output specifies the dose per injection based on a once or twice daily administration schedule.
• Bolus (Prandial) Dose: The portion of the TDD provided by rapid-acting insulin to cover meals. The output specifies the dose per meal.
• Insulin Sensitivity Factor (ISF): Also known as the correction factor, this value estimates how much one unit of rapid-acting insulin will lower blood glucose.
• Insulin-to-Carb Ratio (ICR): This estimates the number of carbohydrate grams covered by one unit of rapid-acting insulin.
• Example Correction Scale: A sample sliding scale based on the calculated ISF, showing suggested correction doses for blood glucose levels above the target range.

How to Use the Calculator

To generate a dosing recommendation, follow these steps by entering the required patient information:

1. Patient Data: Input the patient's weight (in kg or lbs), select their diabetes type, and choose the clinical context that best fits their situation (e.g., insulin-naïve, transitioning from an IV infusion).
2. TDD Calculation Method: Choose either a weight-based calculation, which uses a dosing factor (units/kg/day), or manual entry if the TDD is already known. The tool recommends a starting factor based on the selected clinical context.
3. Dose Distribution: Define the ratio between basal and bolus insulin (typically 50/50) and select the administration frequency for both basal (once or twice daily) and bolus (per meal) insulins.
4. Correction Factors: Select the appropriate "Rule" to calculate the ISF and ICR. The "Rule of 1800" for ISF and "Rule of 500" for ICR are standard for rapid-acting insulin analogs.

Dosing Overview

Basal-bolus therapy is designed to mimic the natural insulin secretion of a healthy pancreas. It involves two types of insulin:

• Basal Insulin: A long-acting insulin (e.g., glargine, detemir, degludec) administered once or twice daily. It provides a constant, low level of insulin to manage glucose levels between meals and overnight.
• Bolus Insulin: A rapid- or short-acting insulin (e.g., lispro, aspart, glulisine) taken before meals to control the rise in blood glucose from carbohydrate intake. A correction dose of bolus insulin may also be used to lower high blood glucose levels.

The Total Daily Dose (TDD) is the cornerstone of initiating therapy. A common starting point is 0.4-0.5 units/kg/day, which is then split, often 50% as basal and 50% as bolus, with the bolus portion divided among meals.

Switching Between Formulations

Transitioning from IV to Subcutaneous Insulin

When a patient is transitioning from a continuous intravenous (IV) insulin infusion to a subcutaneous (SubQ) basal-bolus regimen, a dose adjustment is crucial. Subcutaneous insulin has higher bioavailability than IV insulin. To prevent hypoglycemia, it is standard practice to reduce the total daily dose calculated from the IV infusion rate by 20%. The calculator automatically applies this reduction when the "Transitioning from IV Insulin" status is selected.

Missed Dose Information

Patients should be educated on how to manage a missed dose. General guidance includes:

• Missed Basal Dose: If a dose of long-acting insulin is missed, the patient should consult their healthcare provider. Depending on the insulin type and time elapsed, they may be advised to take the dose late, take a partial dose, or skip it and monitor blood glucose more frequently.
• Missed Bolus Dose: If a mealtime dose is missed, it's often best to check blood glucose and take a correction dose if needed, rather than taking the full meal dose long after eating, which can cause hypoglycemia. The next meal dose should be taken as scheduled.

This advice is general; specific instructions must be provided by a qualified healthcare professional tailored to the patient's regimen.

Safety Alerts

This tool is for educational and estimation purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. All calculations and dosing regimens must be confirmed and individualized by a qualified healthcare provider before administration.

• Hypoglycemia Risk: The primary risk of insulin therapy is hypoglycemia (low blood glucose). Initial doses should be conservative, especially in the elderly or those with renal or hepatic impairment. Patients must be educated on recognizing and treating hypoglycemia.
• Monitoring is Essential: Frequent blood glucose monitoring is critical to assess the patient's response and safely titrate insulin doses.
• Individualization of Therapy: The calculated doses are starting points. Factors like diet, physical activity, stress, illness, and concomitant medications will affect insulin requirements.

Frequently Asked Questions (FAQ)

1. Why is the default dosing factor 0.4-0.5 units/kg/day?

This range is a widely accepted and conservative starting point for most insulin-naïve adult patients with Type 1 or Type 2 diabetes, as recommended by major clinical guidelines. It helps minimize the initial risk of hypoglycemia.

2. What is the difference between the "Rule of 1800" and "Rule of 1500"?

The "Rule of 1800" is used to calculate the Insulin Sensitivity Factor (ISF) for rapid-acting insulin analogs (lispro, aspart, glulisine). The "Rule of 1500" is used for regular (short-acting) human insulin. The calculator defaults to 1800, as rapid-acting analogs are more commonly used in modern basal-bolus regimens.

3. How does the calculator account for insulin resistance (e.g., from steroid use)?

By selecting "Known Insulin Resistance" under Patient Status, the calculator suggests a higher starting TDD factor (e.g., 0.7-1.5+ units/kg/day) to overcome the reduced insulin sensitivity caused by conditions like obesity or medications like corticosteroids.

4. Why is there a 20% dose reduction for IV-to-SubQ transitions?

This reduction accounts for the difference in bioavailability and absorption between continuous intravenous infusion and subcutaneous injections. It is a safety measure to prevent hypoglycemia when switching from a hospital-based IV drip to a home-based injection schedule.

5. Can I use this calculator for pediatric patients?

No. This calculator is designed and validated for adult patients only. Pediatric insulin dosing is highly specialized and requires different calculations and considerations.

6. How is the example correction scale generated?

The scale is created using the calculated Insulin Sensitivity Factor (ISF). It determines how many units of rapid-acting insulin are needed to lower blood glucose by a set amount (e.g., 50 mg/dL) back towards the target, providing a simple guide for patients to correct high readings.

7. Why does the basal/bolus ratio matter?

The 50/50 split is a common starting point, but this ratio often needs adjustment. Patients with high fasting glucose may need a higher percentage of basal insulin (e.g., 60%), while those with significant post-meal spikes may need a higher bolus percentage.

8. What is the difference between ISF and ICR?

ISF (Insulin Sensitivity Factor) relates to correction doses—how much 1 unit of insulin lowers existing high blood glucose. ICR (Insulin-to-Carb Ratio) relates to mealtime doses—how many grams of carbohydrates 1 unit of insulin will cover.

References

• 1. ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S140-S157. doi:10.2337/dc23-S009
• 2. Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The Evolution of Insulin and How it Informs Therapy and Treatment Choices. Endocr Rev. 2020;41(5):733-755. doi:10.1210/endrev/bnaa015
• 3. American Association of Clinical Endocrinology. AACE Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Link
• 4. Umpierrez GE, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222-232. doi:10.1038/nrendo.2016.15